G2G Bio Signs InnoLAMP Platform Evaluation Agreement with UBT
InnoLAMP Applied to UBT Drug Candidates; Development Potential to Be Assessed Over 12 Months
G2G Bio will assess the potential to develop long-acting injectable drugs using drug candidates from United Biotechnology (UBT).
G2G Bio announced on October 19 that it had signed an InnoLAMP platform evaluation agreement and a material transfer agreement with UBT. Under the agreements, G2G Bio will apply InnoLAMP to specific drug candidates provided by UBT and assess their potential for development as long-acting injectable drugs over 12 months.
After signing a research collaboration agreement with a global pharmaceutical company in Europe in September 2025, G2G Bio signed a three-party agreement in March 2026 with Samsung Bioepis and Epis NexLab to develop long-acting injectable treatments for obesity and secure platform technology.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A G2G Bio official said, "Long-acting injectables using the InnoLAMP platform have been validated by multiple global companies," adding, "We expect the evaluation to be completed soon."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
